All Articles by Author:


Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase I Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

[Adverum Biotechnologies, Inc.] Adverum Biotechnologies, Inc. announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase I clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD).

Open Science Takes On the Coronavirus Pandemic

[Nature Technology Feature] When reports emerged in late 2019 of an outbreak of a new coronavirus centred in Wuhan, China, researchers at the virological-analysis website Nextstrain were ready. The open-source project tracks the spread of viruses through genetic variations in the sequences that scientists find.

Director of US Agency Key to Vaccine Development Leaves Role Suddenly Amid Coronavirus Pandemic

[STAT News] Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization.


Truqap Plus Faslodex Approved in the EU for Patients with Advanced ER-Positive Breast Cancer

[AstraZeneca] AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with ER-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.

Breast Cancer Exploits Neural Signaling Pathways for Bone-to-Meninges Metastasis

[Science] Scientists applied a combination of intravital and ex vivo three-dimensional confocal microscopy, micro–computed tomography, and histologic analyses to mouse models of bone-metastatic breast cancer and leptomeninges (LM) metastasis,. They demonstrated that breast cancer cells could traffic to the LM from the bone marrow through abluminal emissary vein migration.

RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis

[Cancer Research] Investigators employed a CRISPR/Cas9 screening strategy that revealed RUVBL1 and RUVBL2 as putative targets. Loss of RUVBL1/2 preferentially impaired the growth of YTHDF1-high colorectal cancer (CRC) cells, patient-derived primary CRC organoids, and subcutaneous xenografts.